Business Context and Reporting Period
This Form 8-K, filed on June 22, 2021, reports on a special meeting of stockholders held by Millendo Therapeutics, Inc. (the "Company") regarding a proposed merger with Tempest Therapeutics, Inc. ("Tempest"). The filing details the voting results for proposals related to the Agreement and Plan of Merger dated March 29, 2021, under which Tempest would become a wholly-owned subsidiary of Millendo.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Millendo or Tempest. This report focuses exclusively on corporate governance events and voting outcomes.
Material Changes and Voting Results
At the Special Meeting, 11,427,443 shares were represented, constituting a quorum out of 19,043,034 shares outstanding. Stockholders approved all four proposals:
- Proposal 1 (Merger Approval): Approved with 6,042,077 votes For, 721,435 Against, and 21,279 Abstentions. This authorizes the issuance of Millendo common stock to Tempest stockholders and the change of control.
- Proposal 2 (Reverse Stock Split): Approved with 10,345,320 votes For, 1,049,922 Against, and 32,201 Abstentions. This amends the certificate of incorporation to effect a reverse stock split of Millendo common stock at a ratio of 1-for-10 to 1-for-15.
- Proposal 3 (Executive Compensation): Approved on a nonbinding advisory basis with 9,684,256 votes For, 1,643,983 Against, and 99,204 Abstentions.
- Proposal 4 (Adjournment): Approved, though adjournment was deemed unnecessary as sufficient votes were received to adopt the Merger Agreement.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the transaction's consummation, future plans, and financial condition. Management highlighted several risks that could cause actual results to differ from expectations, including:
- Failure to satisfy conditions for closing, such as obtaining stockholder approval or completing financing.
- Uncertainties regarding the timing of the transaction and the ability of both companies to consummate it.
- Risks related to Millendo's continued listing on the Nasdaq Stock Market until closing.
- Uncertainties in estimating operating and transaction expenses, which could impact the combined company's cash resources.
- Intellectual property protection risks and competitive responses.
Investor Verification Checklist
- Verify the final closing date of the merger between Millendo and Tempest.
- Confirm the specific reverse stock split ratio (between 1-for-10 and 1-for-15) selected by the Board of Directors.
- Review the definitive proxy statement/prospectus filed on May 11, 2021, for detailed terms of the merger and executive compensation.
- Monitor Millendo's Nasdaq listing status and compliance requirements leading up to the transaction closing.
- Assess the combined company's cash position and financing status post-merger.